Syntara Limited has raised A$10 million through a two-tranche placement and share purchase plan, backing its Phase 2b myelofibrosis trial and multiple clinical readouts following positive FDA feedback.
- A$8 million institutional placement with strong investor support
- A$2 million share purchase plan for existing shareholders
- Funds to support five clinical trial readouts in 2026
- Preparation for Phase 2b myelofibrosis study and patent strengthening
- Placement shares priced at 15.6% discount to last close
Capital Raise Anchored by Positive FDA Review
Syntara Limited (ASX:SNT) has secured firm commitments for an A$8 million institutional placement and plans a further A$2 million share purchase plan, aiming to bolster its cash runway through to Q3 2027. This capital injection follows the company’s recent positive Type C meeting outcome with the US FDA, which endorsed the Phase 2b clinical trial design for its lead asset, amsulostat, targeting myelofibrosis (MF), a debilitating bone marrow cancer.
The placement shares are priced at A$0.027 each, representing a 15.6% discount to Syntara’s last closing price before the announcement. The company will issue approximately 296 million new shares across two tranches, with the first tranche raising A$6.6 million via existing placement capacity and the second tranche, worth A$1.4 million, subject to shareholder approval at an upcoming extraordinary general meeting.
Funding Clinical Readouts and Pipeline Development
The proceeds from the capital raise are earmarked to fund five key clinical trial readouts scheduled throughout 2026. These readouts span Syntara’s three pipeline programs, including amsulostat’s ongoing studies and other candidates targeting fibrosis and inflammation. The company also intends to advance licensing discussions, which remain a critical component of its commercial strategy.
Preparatory work for the Phase 2b MF trial will receive a significant share of the funds, covering protocol finalisation, contract research organisation selection, trial site negotiations, formulation development, and clinical trial supplies. Strengthening Syntara’s global pan-LOX patent portfolio is also a priority, aiming to enhance protection and broaden potential indications for its drug candidates.
CEO Gary Phillips highlighted the strong investor response, attributing it to the positive FDA review and the company’s progress across multiple clinical fronts. The capital raise positions Syntara to capitalise on upcoming data milestones and explore commercial opportunities arising from its pipeline. This momentum builds on the company’s recent clinical advances, including encouraging Phase 2a results for amsulostat and regulatory progress in Europe.
Share Purchase Plan Offers Existing Investors Participation
Alongside the institutional placement, Syntara is launching a non-underwritten share purchase plan (SPP) for existing eligible shareholders in Australia and New Zealand. The SPP allows shareholders to increase their holdings by up to A$30,000 at the same discounted issue price, without brokerage fees. The company expects to raise approximately A$2 million through this offer, which may be scaled back at management’s discretion.
Settlement of the first tranche of placement shares is anticipated by 6 May 2026, with new shares expected to commence trading the following day. The second tranche and SPP shares are scheduled for issuance in mid to late June, pending shareholder approval.
Pipeline Progress Beyond Myelofibrosis
While amsulostat remains the flagship program, Syntara is also advancing other candidates. The topical pan-LOX inhibitor SNT-9465 is in Phase 1a/b trials for hypertrophic scars, and the company continues its collaboration with Professor Fiona Wood and the University of Western Australia on SNT-6302 for keloid scars. Additionally, SNT-4728 is being studied with Parkinson’s UK as a potential treatment for sleep disorders and neurodegenerative diseases, including Parkinson’s, by targeting neuroinflammation.
These developments underscore Syntara’s diversified approach to extracellular matrix dysfunction and fibrosis-related diseases, leveraging its expertise in amine oxidase chemistry. The company’s recent clinical momentum, including the encouraging Phase 2a results and regulatory progress in Europe, provide a foundation for the upcoming trial readouts and licensing efforts.
Bottom Line?
Syntara’s A$10 million capital raise secures runway through critical clinical milestones but hinges on successful Phase 2b execution and partnership deals.
Questions in the middle?
- Will shareholder approval for the second tranche proceed smoothly at the upcoming EGM?
- How will upcoming clinical readouts influence Syntara’s licensing negotiations and valuation?
- Can Syntara leverage its strengthened patent portfolio to broaden indications beyond myelofibrosis?